Fanconi anemia: current management - PubMed (original) (raw)
Review
. 2005:10 Suppl 1:108-10.
doi: 10.1080/10245330512331390096.
Affiliations
- PMID: 16188650
- DOI: 10.1080/10245330512331390096
Free article
Review
Fanconi anemia: current management
Hoon Kook. Hematology. 2005.
Free article
Abstract
Fanconi anemia (FA) is an autosomal recessive chromosomal instability disorder, characterized by congenital anomalies, defective hematopoiesis and a high risk of developing acute myeloid leukemia and certain solid tumors. All racial and ethnic groups are at risk, and at least 11 complementation groups have been identified and the genes defective in eight of these have been identified (FANCA, C, D2, E, F, G, L and BRCA2). FA-A is the most common complementation group, accounting for approximately 65% of all affected individuals. The gold-standard screening test for FA is based on the characteristic hypersensitivity of FA cells to the crosslinking agents, such as mitomicin C or diepoxybutane. Recent progress has been made in identifying the genes bearing pathogenetically relevant mutations, but slower progress has been made in defining the precise functions of the proteins in normal cells, in part because that the proteins are multifunctional. Molecular studies have established that a common pathway exist, both between the FA proteins and other proteins involved in DNA repair such as NBS1, ATM, BRCA1 and BRCA2. Stem cell transplantation (SCT) is the only option for establishing normal hematopoiesis. To reduce undue toxicities due to inherent hypersensitivity, nonmyeloablative conditioning for transplants has been advocated. This review summarizes the general clinical and hematologic features and the current management of FA. Fanconi anemia (FA) is the commonest type of inherited bone marrow failure syndrome with the birth incidence of around three per million. The inheritance pattern is autosomal recessive with the estimated heterozygote frequency being one in 300 in Europe and the US.
Similar articles
- Fanconi anaemia and leukaemia - clinical and molecular aspects.
Tischkowitz M, Dokal I. Tischkowitz M, et al. Br J Haematol. 2004 Jul;126(2):176-91. doi: 10.1111/j.1365-2141.2004.05023.x. Br J Haematol. 2004. PMID: 15238138 Review. - Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG. Hussain S, et al. Hum Mol Genet. 2003 Oct 1;12(19):2503-10. doi: 10.1093/hmg/ddg266. Epub 2003 Aug 5. Hum Mol Genet. 2003. PMID: 12915460 - [Progress of research on protein composition and gene therapy of Fanconi anaemia - review].
Li ZY, Zou YF, Deng YB. Li ZY, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Apr;12(2):231-5. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004. PMID: 15157341 Review. Chinese. - Current clinical management of Fanconi anemia.
Smith AR, Wagner JE. Smith AR, et al. Expert Rev Hematol. 2012 Oct;5(5):513-22. doi: 10.1586/ehm.12.48. Expert Rev Hematol. 2012. PMID: 23146055 Review. - [Complex role of the FA proteins in providing genome stability].
Kluzek K, Zdzienicka MZ. Kluzek K, et al. Postepy Biochem. 2005;51(4):387-94. Postepy Biochem. 2005. PMID: 16676573 Review. Polish.
Cited by
- Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo.
Li Y, Chen S, Yuan J, Yang Y, Li J, Ma J, Wu X, Freund M, Pollok K, Hanenberg H, Goebel WS, Yang FC. Li Y, et al. Blood. 2009 Mar 5;113(10):2342-51. doi: 10.1182/blood-2008-07-168138. Epub 2009 Jan 7. Blood. 2009. PMID: 19129541 Free PMC article. - An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia.
Zhou Y, He Y, Xing W, Zhang P, Shi H, Chen S, Shi J, Bai J, Rhodes SD, Zhang F, Yuan J, Yang X, Zhu X, Li Y, Hanenberg H, Xu M, Robertson KA, Yuan W, Nalepa G, Cheng T, Clapp DW, Yang FC. Zhou Y, et al. Haematologica. 2017 Jun;102(6):1017-1027. doi: 10.3324/haematol.2016.158717. Epub 2017 Mar 24. Haematologica. 2017. PMID: 28341737 Free PMC article. - Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.
Si Y, Ciccone S, Yang FC, Yuan J, Zeng D, Chen S, van de Vrugt HJ, Critser J, Arwert F, Haneline LS, Clapp DW. Si Y, et al. Blood. 2006 Dec 15;108(13):4283-7. doi: 10.1182/blood-2006-03-007997. Epub 2006 Aug 31. Blood. 2006. PMID: 16946306 Free PMC article. - Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.
Saha A, Palchaudhuri R, Lanieri L, Hyzy S, Riddle MJ, Panthera J, Eide CR, Tolar J, Panoskaltsis-Mortari A, Gorfinkel L, Tkachev V, Gerdemann U, Alvarez-Calderon F, Palato ER, MacMillan ML, Wagner JE, Kean LS, Osborn MJ, Kiem HP, Scadden DT, Olson LM, Blazar BR. Saha A, et al. Blood. 2024 May 23;143(21):2201-2216. doi: 10.1182/blood.2023023549. Blood. 2024. PMID: 38447038 - Transcriptome from opaque cornea of Fanconi anemia patient uncovers fibrosis and two connected players.
Chauhan BK, Medsinge A, Scanga HL, Chu CT, Nischal KK. Chauhan BK, et al. Mol Genet Metab Rep. 2021 Jan 27;26:100712. doi: 10.1016/j.ymgmr.2021.100712. eCollection 2021 Mar. Mol Genet Metab Rep. 2021. PMID: 33552906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous